Skip to main content
OpenTrials
Completed

NCT Number: NCT04473404

Effect of a Probiotic Water on Oral Health in Adults

The purpose of this study is to evaluate the effects of consuming a probiotic on salivary, plaque, and tongue bacteria, as well as oral malodor (bad breath). Healthy volunteers will consume a probiotic powder, or a placebo powder, that is dissolved in water for 4 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Salus Research, Inc.

Fort Wayne, Indiana, 46825, United States

About this study

The oral cavity houses one of the most diverse microbiota in the human body. There are nearly 800 unique oral bacterial species identified with more species expected to be added with further sampling and identification. As with microbiota of other sites in the body, a balanced oral microbiota is essential to maintaining the health of the human host. Streptococcus salivarius is a pioneer species that colonizes the human oral cavity from birth, and remains a predominant member of the commensal microbiota throughout life. The commensal microbiota provides protection against pathogenic species associated with conditions such as dental caries, periodontal disease, and oral malodor (halitosis). This randomized, double-blind, placebo-controlled study is conducted to investigate the effect of a Streptococcus salivarius DB-B5 strain on oral bacteria levels and halitosis. Doses of 2 billion and 10 billion colony forming units (CFU) per day are tested.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults, 18 to 65 years of age and in good general health and good oral health (no active or uncontrolled diseases or conditions).
  • Presence of at least 20 natural teeth, excluding third molars.
  • Read and sign the Research Subject Information and Consent Form.
  • Have an OralChroma reading ≥ 125 ppb hydrogen sulfide (H2S) gas, volatile sulfur compound (VSC) (at least 8-12 hours after eating or drinking or oral hygiene) at Baseline.
  • Willingness to use the assigned products according to instructions, attend scheduled appointments, and likelihood of completing the study.
  • Males and females with reproductive potential agree to use medically acceptable contraception, as determined by the investigator, for the duration of the study and 30 days after study completion and attest to having used it for three months prior to screening.
  • Females of child-bearing potential agree to submit to a urine pregnancy test at screening and at the end of the study.

Exclusion criteria

  • Fewer than 20 natural, uncrowned teeth.
  • Active or chronic dental disease.
  • Self-reported dry mouth (xerostomia) by questionnaire.
  • Have had or used any of the following in the past three months: antibiotic treatment, a dental cleaning, mouthrinse.
  • Regular use of probiotic supplements or regular consumption of probiotic rich foods such as yoghurt or kefir in the past month.
  • Require antibiotic prophylaxis for dental or any treatment.
  • Removable or fixed dental appliances (no implants; crowns allowed if subject has at least 20 uncrowned teeth)
  • Pregnant or planning to become pregnant during the study period, or breastfeeding.
  • Uses tobacco products (including smokeless, vaping, and nicotine chewing gums/sprays/lozenges).
  • Chronic or acute illness such as heart disease, diabetes, cancer, autoimmune condition or HIV that could impact outcome of the study in the opinion of the investigator.
  • Use of a dental product or is on a medication/treatment that could impact outcome of the study in the opinion of the investigator.
  • Is unwilling or unable to provide informed consent and follow study procedures.
  • Has participated in any clinical study within 30 days.
  • Clinical site personnel or relative or partner of clinical site personnel.
  • Any other condition or situation that may increase the risk associated with study participation or may interfere with the study results in the opinion of the investigator.

Treatment and study plan

Streptococcus salivarius DB-B5 - 2 billion CFU/day

Dietary Supplement

The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.

Streptococcus salivarius DB-B5 - 10 billion CFU/day

Dietary Supplement

The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.

Placebo

Other

The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.

Primary outcomes

  1. Oral bacteria levels in saliva and plaque

    Time frame: 4 weeks

    Change in the levels of the following bacteria in the saliva, and in samples of supra- and subgingival plaque: Streptococcus salivarius (total), Streptococcus salivarius DB-B5 (probiotic strain), Streptococcus mutans and Porphyromonas gingivalis.

  2. Oral bacteria levels on the tongue

    Time frame: 4 weeks

    Change in the levels of the following bacteria in back-of-tongue samples: Tannerella forsythia, Prevotella (total), Streptococcus salivarius (total) and Streptococcus salivarius DB-B5 (probiotic strain).

  3. Oral malodor

    Time frame: 4 weeks

    Change in OralChroma malodor readings.

Sponsors and collaborators

Lead sponsor

Dose Biosystems Inc.

Industry

Registry information

Official study title

Evaluation of the Effect of an Oral Probiotic on Oral Bacteria and Malodor

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 16, 2020
Registry last updated
Sep 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.